TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19040173

Group type: EXPERIMENTAL
Intervention: Medicare Health Support (MHS) pilot program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Care management services
Number of subjects: 0
Study: 17006356

Group type: EXPERIMENTAL
Intervention: Mime therapy
Number of subjects: 48
Study: 12940805

Group type: EXPERIMENTAL
Intervention: Naratriptan (2.5-mg tablet)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Naproxen (500-mg capsule)
Number of subjects: 12
Study: 10861337

Group type: EXPERIMENTAL
Intervention: Choline supplementation (8.425 g choline citrate)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Choline supplementation
Number of subjects: 14
Study: 9292451

Group type: EXPERIMENTAL
Intervention: Water immersion for 30 min (WI)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Water immersion for 30 min with thigh cuff inflation (WI+Occl)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Seated nonimmersed control with 15 min of thigh cuff inflation (Occl)
Number of subjects: 6
Study: 8210986

Group type: EXPERIMENTAL
Intervention: Cyclosporin A retention enemas (250 mg daily)
Number of subjects: 13
Study: 3538802

Group type: EXPERIMENTAL
Intervention: Reperfusion strategy
Number of subjects: 884

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Supportive therapy (beta-blockade and calcium antagonists)
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Symptom-limited bicycle stress test
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Clinical variables, stress testing, and/or resting radionuclide ventriculography
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Low ejection fraction (<40%) and insufficient blood pressure rise (<30 mm Hg) during stress testing
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory electrocardiogram
Number of subjects: 884
Study: 29520772

Group type: EXPERIMENTAL
Intervention: Twice daily kiwifruit consumption for 5 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no kiwifruit consumption)
Number of subjects: 0
Study: 27804312

Group type: EXPERIMENTAL
Intervention: Montgomery‐Åsberg Depression Self‐assessment scale (MADRS‐S)
Number of subjects: 9
Study: 24150198

Group type: EXPERIMENTAL
Intervention: Fixed high (FH; 0.067 mg/kg/day)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Individually adjusted (IA; 0.035 mg/kg/day) after 3 months
Number of subjects: 89

Group type: COMPARATOR
Intervention: Individually adjusted (IA; 0.035 mg/kg/day) continued low dose
Number of subjects: 89
Study: 23869636

Group type: EXPERIMENTAL
Intervention: Screen capture tutorials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control variables
Number of subjects: 0
Study: 21554564

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 18794652

Group type: EXPERIMENTAL
Intervention: Quetiapine (titrated up to 400 mg/d, then 400-600 mg/d depending on clinical response)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16644334

Group type: EXPERIMENTAL
Intervention: Azimilide 125 mg twice daily for 3 days then once daily
Number of subjects: 446

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446
Study: 12953018

Group type: EXPERIMENTAL
Intervention: Higher sodium intake (140 mmol/d)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Medium sodium intake (104 mmol/d)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Lower sodium intake (62 mmol/d)
Number of subjects: 188
Study: 10844829

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micrograms kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl 25-50 micrograms kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl 100 and 150 micrograms kg‐1
Number of subjects: 40
Study: 8844441

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 10 mg
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 20 mg
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 30 mg
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Immediate-release oxycodone 15 mg
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Immediate-release oxycodone 10 mg plus acetaminophen 650 mg (APAP)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 1727961

Group type: EXPERIMENTAL
Intervention: Interposed abdominal counterpulsation (IAC) during CPR
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 103
Study: 6653683

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (SRT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30408621

Group type: EXPERIMENTAL
Intervention: SINEMA model (intervention arm)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 125
Study: 29248312

Group type: EXPERIMENTAL
Intervention: Nurses (Group N)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Physicians (Group P)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 544

Group type: COMPARATOR
Intervention: Men
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 544

Group type: COMPARATOR
Intervention: Physicians
Number of subjects: 544

Group type: COMPARATOR
Intervention: Age, job seniority, and type of hospital
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Night shifts and duty overload
Number of subjects: 544
Study: 26347514

Group type: EXPERIMENTAL
Intervention: SQT+NAC (N-acetylcysteine 400 mg bid for the first 5 days)
Number of subjects: 99

Group type: COMPARATOR
Intervention: SQT-only (rabeprazole 20 mg and amoxicillin 1 g for the first 5 days, followed by rabeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg for the remaining 5 days)
Number of subjects: 99

Group type: COMPARATOR
Intervention: SQT-only
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: SQT+NAC
Number of subjects: 99
Study: 25494054

Group type: EXPERIMENTAL
Intervention: 0.3 g·kg‐1 BICA
Number of subjects: 21

Group type: COMPARATOR
Intervention: 4 g of sodium chloride (placebo)
Number of subjects: 21
Study: 23021296

Group type: EXPERIMENTAL
Intervention: Experimental group received a brief note asking to increase physical activity and sun exposure
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group did not receive explicit recommendations
Number of subjects: 15
Study: 20068208

Group type: EXPERIMENTAL
Intervention: PRP injection
Number of subjects: 54

Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Comparison of PRP vs. placebo
Number of subjects: 54
Study: 17321097

Group type: EXPERIMENTAL
Intervention: Booklet on cigarette additives (n=1074)
Number of subjects: 2152

Group type: COMPARATOR
Intervention: Control group (n=1078)
Number of subjects: 2152
Study: 16267182

Group type: EXPERIMENTAL
Intervention: Intermediate care (IC) service provided by a joint care management team assessing patient need and purchasing support and rehabilitation from sector-based IC teams.
Number of subjects: 1648

Group type: EXPERIMENTAL
Intervention: Intermediate care (IC) service
Number of subjects: 1648

Group type: COMPARATOR
Intervention: Control group (no IC service)
Number of subjects: 1648
Study: 12391531

Group type: EXPERIMENTAL
Intervention: Hyperventilation (p(et)CO(2)=30 mmHg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normoventilation (p(et)CO(2)=45 mmHg)
Number of subjects: 120
Study: 10201671

Group type: EXPERIMENTAL
Intervention: 15 microg nalmefene
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 25 microg nalmefene
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study: 8641322

Group type: COMPARATOR
Intervention: SCH 42354 400 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: SCH 42354 300 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: SCH 42354 (entire dose range)
Number of subjects: 0
Study: 2138704

Group type: EXPERIMENTAL
Intervention: 5 mg ramipril p.o.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6158390

Group type: EXPERIMENTAL
Intervention: Aspirin therapy for 1 week
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo therapy for 48 h
Number of subjects: 6
Study: 31158253

Group type: EXPERIMENTAL
Intervention: Biological Hall technique (HT)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Conventional technique (CT)
Number of subjects: 212
Study: 28726053

Group type: EXPERIMENTAL
Intervention: Knee immobilization brace (KIB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Knee immobilizer brace and Foot Lifter Orthosis (FLO)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Knee immobilization brace (KIB) and rigid taping (RT)
Number of subjects: 20
Study: 25981651

Group type: EXPERIMENTAL
Intervention: Hange-shashin-to; administered to 12 patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: No Hange-shashin-to; 4 patients
Number of subjects: 16
Study: 24058300

Group type: EXPERIMENTAL
Intervention: Oral tenofovir and emtricitabine/tenofovir with adherence counseling
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1147
Study: 21939520

Group type: EXPERIMENTAL
Intervention: Budesonide (800 μg daily for 3 months)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 20025153

Group type: EXPERIMENTAL
Intervention: Hydrophilic catheters
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard catheters
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Self-reporting of UTI signs and symptoms
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Signs and symptoms of UTI
Number of subjects: 56
Study: 18997196

Group type: EXPERIMENTAL
Intervention: rosuvastatin, 20 mg daily
Number of subjects: 17802

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17802
Study: 16243115

Group type: EXPERIMENTAL
Intervention: Resveratrol (70 microM)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Resveratrol (20 microM)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Resveratrol combined with l-NOARG (10(‐4) M)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Indomethacin (10(‐5) M)
Number of subjects: 38
Study: 11876271

Group type: EXPERIMENTAL
Intervention: 50 masticatory cycles
Number of subjects: 12

Group type: COMPARATOR
Intervention: 25 masticatory cycles (swallowing ham cubes whole)
Number of subjects: 12
Study: 10202985

Group type: EXPERIMENTAL
Intervention: Cytokine-induced inflammation markers (IL-1ra, ESR, CRP, PMNL count)
Number of subjects: 41
Study: 7595908

Group type: EXPERIMENTAL
Intervention: Low-dose verapamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil and nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 0
Study: 2205287

Group type: EXPERIMENTAL
Intervention: Soft vacuum extractor cups (Silc or Silastic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rigid vacuum extractor cups (New Bird or O'Neil)
Number of subjects: 0
Study: 69938

Group type: EXPERIMENTAL
Intervention: Topical thrombin applied locally to the wound
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no thrombin applied)
Number of subjects: 45
Study: 31010412

Group type: EXPERIMENTAL
Intervention: Web-based intervention program
Number of subjects: 22
Study: 28803124

Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum with moderate neuromuscular blockade (1-3 TOF)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum with deep neuromuscular blockade (1-5 PTC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum (12mmHg)
Number of subjects: 90
Study: 25811395

Group type: EXPERIMENTAL
Intervention: Internet‐mediated, pedometer‐based exercise intervention
Number of subjects: 239

Group type: COMPARATOR
Intervention: Wait-list control group (pedometer)
Number of subjects: 239
Study: 23437966

Group type: EXPERIMENTAL
Intervention: Paroxetine (6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alprazolam (after 6 weeks of paroxetine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mirtazapine (after long-term paroxetine treatment)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Paroxetine (long-term treatment, 18.7 weeks on average)
Number of subjects: 30
Study: 21752726

Group type: COMPARATOR
Intervention: Placebo intervention (identically-looking placebo drug)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Active drug (homeopathic remedy)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 45
Study: 18515447

Group type: EXPERIMENTAL
Intervention: THC 8 mg
Number of subjects: 12
Study: 17070276

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 12798881

Group type: EXPERIMENTAL
Intervention: Combination of 0.625 mg of esterified estrogens and 1.25 mg of methyltestosterone
Number of subjects: 218

Group type: COMPARATOR
Intervention: 0.625 mg of esterified estrogens
Number of subjects: 218
Study: 10951298

Group type: EXPERIMENTAL
Intervention: Mild vascular dilation and tortuosity insufficient for plus disease
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal posterior poles
Number of subjects: 32
Study: 8979385

Group type: EXPERIMENTAL
Intervention: Majority group relevant to self-definition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minority group negatively self-relevant
Number of subjects: 0
Study: 1475511

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (SK)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Control group (not treated with fibrinolytic agents)
Number of subjects: 510
Study: 6383615

Group type: EXPERIMENTAL
Intervention: Captopril (CPT) 25 mg + Hydrochlorothiazide (HCT) 25 mg BID
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oxprenolol (OXP) 80 mg + Chlorthalidone (CHLT) 10 mg BID
Number of subjects: 20
Study: 30836169

Group type: EXPERIMENTAL
Intervention: Dyad training (50 min with instructional videos and hands-on exercises)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Instructor-led training (2 hours in groups of six)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Dyad training
Number of subjects: 330

Group type: COMPARATOR
Intervention: Instructor-led training
Number of subjects: 330
Study: 29906455

Group type: EXPERIMENTAL
Intervention: FITOPROT A - mucoadhesive formulation containing 10 mg/mL of curcuminoids extract plus 20% v/v of Bidens pilosa L. extract
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FITOPROT B - mucoadhesive formulation containing 20 mg/mL of curcuminoids extract plus 40% v/v of Bidens pilosa L. extract
Number of subjects: 20
Study: 27491226

Group type: EXPERIMENTAL
Intervention: Berberine Capsule (BC) 300 mg, thrice per day for 3 months
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo 300 mg, thrice per day for 3 months
Number of subjects: 102
Study: 25208824

Group type: EXPERIMENTAL
Intervention: Active stimulation (Deep brain stimulation of the basolateral amygdala)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham stimulation (Control group)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Open-label stimulation (after initial phase)
Number of subjects: 6
Study: 22333403

Group type: EXPERIMENTAL
Intervention: Everolimus introduction with calcineurin inhibitor (CNI) reduction
Number of subjects: 282

Group type: COMPARATOR
Intervention: Standard CNI therapy
Number of subjects: 282
Study: 20150170

Group type: EXPERIMENTAL
Intervention: Web-based personalized feedback intervention (Check Your Drinking - CYD)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control condition (written description of CYD components)
Number of subjects: 185
Study: 18574391

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (75 mg/day with a 300 mg loading dose for 14 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 42
Study: 16042934

Group type: EXPERIMENTAL
Intervention: 1,064 nm Nd:YAG laser
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1,320 nm Nd:YAG laser
Number of subjects: 12
Study: 12358325

Group type: EXPERIMENTAL
Intervention: NPPV + LTOT
Number of subjects: 122

Group type: COMPARATOR
Intervention: LTOT alone
Number of subjects: 122
Study: 10513855

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 29
Study: 7498103

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with a physiological dose of water‐soluble vitamins (fortified fruit juice containing 50 g carbohydrate and 50% of the daily dietary recommendations of water‐soluble vitamins)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Regular fruit juice (placebo)
Number of subjects: 42
Study: 1780420

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 62

Group type: COMPARATOR
Intervention: 0 mg nicotine gum
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cigarette withdrawal
Number of subjects: 62
Study: 7048948

Group type: EXPERIMENTAL
Intervention: Oltipraz 25 mg/kg body weight
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Oltipraz 35 mg/kg body weight
Number of subjects: 62
Study: 31779856

Group type: EXPERIMENTAL
Intervention: Ultra-low contrast delivery technique (ULCD)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard automated contrast injector system (ACIS)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Overall (ULCD)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Overall (ACIS)
Number of subjects: 204
Study: 29425836

Group type: EXPERIMENTAL
Intervention: Smartphone-based daily feedback and communication platform
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine biweekly prenatal clinic care (control group)
Number of subjects: 120
Study: 27168899

Group type: EXPERIMENTAL
Intervention: Facilitated discussion group intervention (18 sessions)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study: 24763866

Group type: EXPERIMENTAL
Intervention: Clinical Significant Medication Errors (CSME)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: CSME
Number of subjects: 200
Study: 23036274

Group type: EXPERIMENTAL
Intervention: Real words (DARK/PARK)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pronounceable pseudowords (DARL/PARL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 11‐year‐olds ERP response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7‐year‐olds ERP response
Number of subjects: 0
Study: 20453626

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study: 18540858

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16114160

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) reactivity to molds extracts
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) reactivity to grass pollen extracts
Number of subjects: 85
Study: 12086380

Group type: EXPERIMENTAL
Intervention: Terminalia arjuna (500 mg 8 hourly)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (40 mg/daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 9695894

Group type: EXPERIMENTAL
Intervention: Pharmacologic therapy (theophylline, inhaled bronchodilators, steroids, antianxiolytics, antidepressants)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General exercise strategies (exercise training, exercise and comprehensive pulmonary rehabilitation, upper extremity training)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle therapy (inspiratory muscle training, inspiratory muscle rest)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specialized nursing care
Number of subjects: 0
Study: 7888387

Group type: EXPERIMENTAL
Intervention: Craniospinal irradiation and chemotherapy
Number of subjects: 27
Study: 2171446

Group type: EXPERIMENTAL
Intervention: Aluminum plus citrate (as Shohl's solution)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Aluminum alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Aluminum plus sodium bicarbonate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Citrate alone
Number of subjects: 8
Study: 622844

Group type: EXPERIMENTAL
Intervention: Ajmaline (50 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lidocaine (100 mg)
Number of subjects: 10
Study: 31195857

Group type: EXPERIMENTAL
Intervention: BM-PHA
Number of subjects: 91

Group type: COMPARATOR
Intervention: Restylane Perlane (PER)
Number of subjects: 91
Study: 30051255

Group type: EXPERIMENTAL
Intervention: Mobile health application for recruitment
Number of subjects: 0
Study: 29262841

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 2000
Study: 26427627

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 23327643

Group type: EXPERIMENTAL
Intervention: Board game intervention (Pick-Klop group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychoeducation group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study: 21278617

Group type: EXPERIMENTAL
Intervention: ACWY‐TT (tetravalent meningococcal conjugate vaccine)
Number of subjects: 1501

Group type: COMPARATOR
Intervention: Men‐PS (licensed tetravalent meningococcal polysaccharide vaccine)
Number of subjects: 1501
Study: 19032560

Group type: COMPARATOR
Intervention: Lidocaine 10 mg/ml
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg/ml
Number of subjects: 30
Study: 17156291

Group type: EXPERIMENTAL
Intervention: HIV vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (rabies vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIV vaccine (administered to placebo patients at trial closeout)
Number of subjects: 0
Study: 15494897

Group type: EXPERIMENTAL
Intervention: Valacyclovir at 1000 mg twice daily for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valacyclovir at 500 mg twice daily
Number of subjects: 0